Tuberculosis and Biologic Therapies Anti-Tumor Necrosis Factor-α and Beyond

被引：51
作者：
Godfrey, Mark S. [1 ]
Friedman, Lloyd N. [1 ]
机构：
[1] Yale Univ, Sch Med, Sect Pulm Crit Care & Sleep Med, 300 Cedar St,TAC S425,POB 208057, New Haven, CT 06520 USA
来源：
CLINICS IN CHEST MEDICINE | 2019年 / 40卷 / 04期
关键词：
Tuberculosis; Biological therapy; Tumor necrosis factor-alpha; Antibodies; Monoclonal; Opportunistic infection; GAMMA RELEASE ASSAYS; ANTI-TNF THERAPY; INTERLEUKIN-12/23; MONOCLONAL-ANTIBODY; RHEUMATOID-ARTHRITIS; MYCOBACTERIUM-TUBERCULOSIS; LATENT TUBERCULOSIS; LONG-TERM; POSTMARKETING SURVEILLANCE; ANKYLOSING-SPONDYLITIS; IMMUNE RECONSTITUTION;
D O I：
10.1016/j.ccm.2019.07.003
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Biologic drugs have revolutionized the treatment of certain hematologic, autoimmune, and malignant diseases, but they may place patients at risk for reactivation or acquisition of tuberculosis. This risk is highest with the tumor necrosis factor-alpha (TNF-alpha) inhibitors. Amongst this class of drugs, the monoclonal antibodies (infliximab, adalimumab, golimumab) and antibody fragment (certolizumab) carry an increased risk compared to the soluble receptor fusion molecule, etanercept. Treatment of latent TB is critical to decrease the risk of reactivation. Data continues to emerge regarding tuberculosis risk associated with novel biologics targeting cytokines involved in tuberculosis control.
引用
收藏
页码：721 / +
页数：20
相关论文
共 152 条
[61]   Blocking IL-1α but not IL-1β increases susceptibility to chronic Mycobacterium tuberculosis infection in mice [J].
Guler, Reto ;
Parihar, Suraj P. ;
Spohn, Gunther ;
Johansen, Pal ;
Brombacher, Frank ;
Bachmann, Martin F. .
VACCINE, 2011, 29 (06) :1339-1346
[62]   Immune Reconstitution Inflammatory Syndrome Associated with Biologic Therapy [J].
Gupta, Malika ;
Jafri, Kashif ;
Sharim, Rebecca ;
Silverman, Susanna ;
Sindher, Sayantani B. ;
Shahane, Anupama ;
Kwan, Mildred .
CURRENT ALLERGY AND ASTHMA REPORTS, 2015, 15 (02) :1-8
[63]   Screening and prevention for latent tuberculosis in immunosuppressed patients at risk for tuberculosis: a systematic review of clinical practice guidelines [J].
Hasan, Tasnim ;
Au, Eric ;
Chen, Sharon ;
Tong, Allison ;
Wong, Germaine .
BMJ OPEN, 2018, 8 (09)
[64]   Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases [J].
Hatzara, Chrisoula ;
Hadziyannis, Emilia ;
Kandili, Anna ;
Koutsianas, Christos ;
Makris, Anastasia ;
Georgiopoulos, Georgios ;
Vassilopoulos, Dimitrios .
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (10) :1848-1853
[65]   YATES CORRECTION FOR CONTINUITY AND THE ANALYSIS OF 2X2 CONTINGENCY-TABLES [J].
HAVILAND, MG .
STATISTICS IN MEDICINE, 1990, 9 (04) :363-367
[66]   The biology and management of non-small cell lung cancer [J].
Herbst, Roy S. ;
Morgensztern, Daniel ;
Boshoff, Chris .
NATURE, 2018, 553 (7689) :446-454
[67]   CONVINCING EVIDENCE FROM CONTROLLED AND UNCONTROLLED STUDIES ON THE LIPID-LOWERING EFFECT OF A STATIN [J].
Higgins, Julian .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (12)
[68]   A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis [J].
Holmen, Carolina ;
Piehl, Fredrik ;
Hillert, Jan ;
Fogdell-Hahn, Anna ;
Lundkvist, Malin ;
Karlberg, Elin ;
Nilsson, Petra ;
Dahle, Charlotte ;
Feltelius, Nils ;
Svenningsson, Anders ;
Lycke, Jan ;
Olsson, Tomas .
MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (06) :708-719
[69]   Transmembrane TNF-α: structure, function and interaction with anti-TNF agents [J].
Horiuchi, Takahiko ;
Mitoma, Hiroki ;
Harashima, Shin-ichi ;
Tsukamoto, Hiroshi ;
Shimoda, Terufumi .
RHEUMATOLOGY, 2010, 49 (07) :1215-1228
[70]   Tuberculosis Screening and Reactivation Among a National Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha Antagonists [J].
Hou, Jason K. ;
Kramer, Jennifer R. ;
Richardson, Peter ;
Sansgiry, Shubhada ;
El-Serag, Hashem B. .
INFLAMMATORY BOWEL DISEASES, 2017, 23 (02) :254-260
234567891011